PCA3 and prostate carcinoma: Moreover, the LBXexo score demonstrated relatively greater diagnostic performance (AUC: 0.736 vs. 0.703) and better specificity (57.1% vs. 36.7%) than PCA3 alone for high-grade prostate cancer.